A Phase 3 interventional study of Jaktinib in Ankylosing Spondylitis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.
Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 23rd largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2023, is one of 18 in phase 3, and was the 49th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18–75
China-Japan Friendship Hospital · Sites in China
Ages 18–75
Huabo Biopharm Co., Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Jiangsu vcare pharmaceutical technology co., LTD · Sites in China
Ages 18–70
China-Japan Friendship Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 22 · Phase 4 17
First in 2005; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 150 across the 62 interventional studies, 440 across the 14 observational. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 76 have an industry lead sponsor. The 10 most frequent:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd has 3 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
9 of the studies in Spondylitis, Ankylosing with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07237568Phase 3Lynk Pharmaceuticals Co., LtdA Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis | 2026-11 |
| NCT06000956Phase 3Tasly Pharmaceutical Group Co., LtdA Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo | 2026-12-01 |
| NCT07261644Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | 2027-01-14 |
| NCT07172360Phase 3Jiangsu vcare pharmaceutical technology co., LTDEfficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | 2027-08-30 |
| NCT07920861Huabo Biopharm Co., Ltd.A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 76 studies in Spondylitis, Ankylosing with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Jaktinib
Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Related Discontinuations at 32 Weeks
Treatment-emergent AEs were events that occurred between first dose of study drug and up to 32 weeks that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to Week 32
Percentage of Participants Achieving ASAS20 Response at Week 4, 8, 12, 16,20,24,28 and 32
ASAS20 assess 4 domains: PGA of Disease (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (BASFI; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: \>= 20% improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.
Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32
Percentage of Participants Achieving ASAS40 Response at Week 4, 8, 12, 16,20,24,28 and 32
ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.
Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32
Change From Baseline in Patient's Assessment of Spinal Pain: Total Back Pain at Week 4, 8, 12, 16,20,24,28 and 32
Participants marked their level of total back pain on a numerical rating scale (NRS) ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.
Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32
Percentage of Participants Achieving ASAS 5/6 Response at Week 4, 8, 12, 16,20,24,28 and 32
ASAS 5/6 consists of 6 domains: 4 used in ASAS20 - PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), Spinal Pain (total back pain) (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), CRP (was measured in mg per liter) and Spinal mobility was measured in centimeter and calculated as mean of right and left measurements of lateral spinal flexion from BASMI. ASAS 5/6: defined as \>=20% improvement in at least 5 domains.
Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32
Ran from Nov 2023 to primary completion in Mar 2026, 27 months.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 27 months is above that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Jaktinib
Suzhou Zelgen Biopharmaceuticals Co.,Ltd →